UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000029838
Receipt number R000034085
Scientific Title Treatment of plasminogen activator in ophthalmology
Date of disclosure of the study information 2017/11/06
Last modified on 2018/11/29 17:57:55

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Treatment of plasminogen activator in ophthalmology

Acronym

Treatment of t-PA in ophthalmology

Scientific Title

Treatment of plasminogen activator in ophthalmology

Scientific Title:Acronym

Treatment of t-PA in ophthalmology

Region

Japan


Condition

Condition

Submacular hemorrhage, Retinal vein occlusion, Fibrin formation due to postoperative inflammation

Classification by specialty

Ophthalmology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the safety of the treatment protocol using a tissue plasminogen activator in ophthalmology.

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Adverse event

Key secondary outcomes

Visual acuity, Visual field, Retinal thickness, Intraocular pressure


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Injecting tissue plasminogen activator(0.025mg/0.1ml)0.02-0.2ml into a subretinal cavity or a retinal vascular in vitreous surgery.
Injecting tissue plasminogen activator(0.025mg/0.1ml)0.05-0.1ml into an anterior chamber or a intravitreal cavity with fibrin formation.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1)Patients who have submacular hemorrhage, RVO, fibrin formation due to postoperative inflammation
(2)Patients who were sufficient explanatation about using t-PA, and could get informed consent.

Key exclusion criteria

(1)Patients who are during lactation or pregnancy or expected pregnancy
(2)Patients who have active eye/eyelid inflammation or disease or infection
(3)Patients who have hemorrhagic diathesis
(4)Patients who are judged to be inappropriate for this trial by the judgement of the doctor.

Target sample size

10


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kazuhisa Sugiyama

Organization

Kanazawa University

Division name

Department of Ophthalmology

Zip code


Address

13-1, Takara-machi, Kanazawa, Ishikawa

TEL

0762652403

Email

ksugi@med.kanazawa-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Toshinori Masaki

Organization

Kanazawa University

Division name

Department of Ophthalmology

Zip code


Address

13-1, Takara-machi, Kanazawa, Ishikawa

TEL

0762652403

Homepage URL


Email

tmasaki@med.kanazawa-u.ac.jp


Sponsor or person

Institute

Department of Ophthalmology, Kanazawa University

Institute

Department

Personal name



Funding Source

Organization

Department of Ophthalmology, Kanazawa University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 11 Month 06 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2017 Year 11 Month 06 Day

Date of IRB


Anticipated trial start date

2017 Year 11 Month 06 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 11 Month 06 Day

Last modified on

2018 Year 11 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034085


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name